Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV protease inhibitor.
A 45-year-old human immunodeficiency virus (HIV)-infected patient has suffered for a period of 4 years from recurrent and, later on, persistent oral pseudomembranous candidosis. The Candida isolates proved to be resistant to azole derivates in vitro and in vivo. Treatment with amphotericin B parenterally was successful in February 1996, but had to be stopped when chemotherapy for lymphoma was started. In August 1996, the patient showed a shift from the pseudomembranous to the erythematous type of oral candidosis; antiretroviral combination therapy including the HIV protease inhibitor saquinavir had been started 4 months previously. In July 1997, the patient was still suffering from a persistent oral candidosis of the erythematous type.
Hoegl
L
L
Department of Dermatology, Ludwig-Maximilians-Universität, Munich, Germany.
Thoma-Greber
E
E
Röcken
M
M
Korting
H C
HC
D002180:Candidiasis, Oral / Q000145:classification* / Q000150:complications; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D009055:Mouth / Q000473:pathology; D019258:Saquinavir / Q000009:adverse effects*
D017320:HIV Protease Inhibitors; D019258:Saquinavir